UNSPSC 51385701: Deracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX29JB5XWV, chemically known as benzenesulfonamide, 4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1h-pyrazol-1-yl)- but generally known as deracoxib, which bears US NIH Compound Identifier 3058754. European Medicines Agency schedules Deracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01594MIG.

UNSPSC 51385701 Deracoxib is a Commodity code that in recent state and local solicitations actually covers a much broader range of pharmaceutical and pharmacy-related products and services than the code name alone suggests. Rather than deracoxib specifically (a veterinary anti-inflammatory), state and local governments are procuring generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems through this code, alongside exploratory procurement focused on direct-to-manufacturer prescription fulfillment models. The issuing bodies include state health and human services agencies, county health departments, and cooperative purchasing alliances that serve multiple state and local jurisdictions. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are active recent buyers; MMCAP's scope extends to participating states including Oregon and subordinate state and local facilities across member jurisdictions.

Activity concentrates in Florida and Minnesota with secondary reach into Texas through exploratory initiatives. The Minnesota Department of Administration issued an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, requiring cGMP and Drug Supply Chain Security Act compliance, $5 million commercial general liability coverage, and pricing submissions in designated Excel format; awards are effective July 1, 2026 for an initial two-year term. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 with a July 26, 2026 deadline to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to explore vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, indicating early-stage procurement planning rather than an active competitive solicitation at this time.